Citations

Mayo Clinic

Clear

807 citation(s) found for "Muñoz-Alía, Miguel".

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial
Richardson, Paul G. , Sonneveld, Pieter , Irwin, David, Stadtmauer, Edward A. , Harousseau, Jean‐Luc, Ben‐Yehuda, Dina, Goldschmidt, Hartmut , Reece, Donna , Bladé, Joan , Boccadoro, Mario , Cavenagh, Jamie, Alsina, Melissa , Rajkumar, S. Vincent , Lacy, Martha Q. , Dalton, William S. , Boral, Anthony, Esseltine, Dixie‐Lee, Schenkein, David P., Richardson, Paul Gerard Guy , Schuster, Michael K. , Facon, Thierry T.F. , Lonial, Sagar , Miguel, Jesús F. San , Jakubowiak, Andrzej , Anderson, Kenneth C. , Rajkumar, S Vincent

Blood | August 9, 2007 | Volume: 110 | Issue: 10 | Pages: 3557-3560

10.1182/blood-2006-08-036947 | PMID 17690257 Get It

Abstract Initial analysis of the Assessment of Proteasome Inhibition for Extending Remissions (APEX) trial of relapsed multiple myeloma patients showed significantly longer time to progression, higher response rate, and improved survival with single-agent bortezomib versus high-dose dexamethasone. In this updated analysis (median follow-up: 22 months), survival was assessed in both arms, and efficacy updated for the bortezomib arm. Median survival was 29.8 months for bortezomib versus 23.7 months for dexamethasone, a 6-month benefit, despite substantial crossover from dexamethasone to bortezomib. Overall and complete response rates with bortezomib were 43% and 9%, respectively; among responding patients, 56% improved response with longer therapy beyond initial response, leading to continued improvement in overall quality of response. Higher response quality (100% M-protein reduction) was associated with longer response duration; response duration was not associated with time to response. These data confirm the activity of bortezomib and support extended treatment in relapsed multiple myeloma patients tolerating therapy. This study is registered at http://clinicaltrials.gov (Study ID NCT00048230).
Proteomic Analysis of Waldenstrom Macroglobulinemia
Hatjiharissi, Evdoxia , Ngo, Hai T., Leontovich, Alexey A. , Leleu, Xavier , Timm, Michael, Melhem, Mona F., George, Diane, Lu, Ganwei, Alsayed, Yazan, Zeismer, Steven C., Cabanela, Miguel E., Nehme, Alex, Jia, Xiaoying , Moreau, Anne Sophie, Fonseca, Rafaël , Ghobrial, Joanna M. , Moreau, Anne Sophie, Treon, Steven P. , Gertz, Morie A. , Anderson, Kenneth C. , Witzig, Thomas E. , Ghobrial, Irene M. , Fonseca, Rafael

Cancer Research | April 17, 2007 | Volume: 67 | Issue: 8 | Pages: 3777-3784

10.1158/0008-5472.can-06-3089 | PMID 17440091 Get It

Abstract To better understand the molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody-based protein microarrays to compare patterns of protein expression between untreated WM and normal bone marrow controls. Protein expression was defined as a >2-fold or 1.3-fold change in at least 67% of the tumor samples. Proteins up-regulated by >2-fold included Ras family proteins, such as Rab-4 and p62DOK, and Rho family proteins, such as CDC42GAP and ROKα. Other proteins up-regulated by >1.3-fold included cyclin-dependent kinases, apoptosis regulators, and histone deacetylases (HDAC). We then compared the samples of patients with symptomatic and asymptomatic WM and showed similar protein expression signatures, indicating that the dysregulation of signaling pathways occurs early in the disease course. Three proteins were different by >2-fold in symptomatic versus asymptomatic, including the heat shock protein HSP90. Elevated protein expression was confirmed by immunohistochemistry and immunoblotting. Functional significance was validated by the induction of apoptosis and inhibition of proliferation using specific HDAC and HSP90 inhibitors. This study, therefore, identifies, for the first time, multiple novel proteins that are dysregulated in WM, which both enhance our understanding of disease pathogenesis and represent targets of novel therapeutics. [Cancer Res 2007;67(8):3777–8]
Congenital endplate acetylcholinesterase deficiency responsive to ephedrine
Bestué-Cardiel, M., Cabezón-Alvarez, A. Sáenz de, Capablo-Liesa, J.L., Pisón, Javier López , Segura, José Luis Peña , Engel, Andrew G. , Martin-Martinez, Javier

Neurology | July 12, 2006 | Volume: 65 | Issue: 1 | Pages: 144-146

10.1212/01.wnl.0000167132.35865.31 | PMID 16009904 Get It

The Human Growth Hormone Gene Contains a Silencer Embedded within an Alu Repeat in the 3′-Flanking Region
Trujillo, Miguel A., Sakagashira, Michiko, Eberhardt, Norman L.

Molecular Endocrinology | June 9, 2006 | Volume: 20 | Issue: 10 | Pages: 2559-2575

10.1210/me.2006-0147 | PMID 16762973 Get It

AbstractAlu family sequences are middle repetitive short interspersed elements (SINEs) dispersed throughout vertebrate genomes that can modulate gene transcription. The human (h) GH locus contains 44 complete and four partial Alu elements. An Sx Alu repeat lies in close proximity to the hGH-1 and hGH-2 genes in the 3′-flanking region. Deletion of the Sx Alu repeat in reporter constructs containing hGH-1 3′-flanking sequences increased reporter activity in transfected pituitary GC cells, suggesting this region contained a repressor element. Analysis of multiple deletion fragments from the 3′-flanking region of the hGH-1 gene revealed a strong orientation- and position-independent silencing activity mapping between nucleotides 2158 and 2572 encompassing the Sx Alu repeat. Refined mapping revealed that the silencer was a complex element comprising four discrete entities, including a core repressor domain (CRD), an antisilencer domain (ASE) that contains elements mediating the orientation-independent silencer activity, and two domains flanking the CRD/ASE that modulate silencer activity in a CRD-dependent manner. The upstream modulator domain is also required for orientation-independent silencer function. EMSA with DNA fragments representing all of the silencer domains yielded a complex pattern of DNA-protein interactions indicating that numerous GC cell nuclear proteins bind specifically to the CRD, ASE, and modulator domains. The silencer is GH promoter dependent and, in turn, its presence decreases the rate of promoter-associated histone acetylation resulting in a significant decrease of RNA polymerase II recruitment to the promoter. The silencer may provide for complex regulatory control of hGH gene expression in pituitary cells.
Colocalization of calcium entry and exocytotic release sites in adrenal chromaffin cells.
Robinson, Iain M. , Finnegan, Jennifer M., Monck, Jonathan R., Fernández, José Miguel Rodríguez , Wightman, Robert Mark

Proceedings of the National Academy of Sciences | May 31, 2006 | Volume: 92 | Issue: 7 | Pages: 2474-2478

10.1073/pnas.92.7.2474 | PMID 7708668 Get It

"Snapshot" images of localized Ca2+ influx into patch-clamped chromaffin cells were captured by using a recently developed pulsed-laser imaging system. Transient opening of voltage-sensitive Ca2+ channels gave rise to localized elevations of Ca2+ that had the appearance of either "hotspots" or partial rings found immediately beneath the plasma membrane. When the Ca2+ imaging technique was employed in conjunction with flame-etched carbon-fiber electrodes to spatially map the release sites of catecholamines, it was observed that the sites of Ca2+ entry and catecholamine release were colocalized. These results provide functional support for the idea that secretion occurs from "active zone"-like structures in neuroendocrine cells.
Authors’ reply
Trousdale, Robert T. , Cabanela, Miguel E., Sierra, Rafael J.

The Journal of Bone and Joint Surgery. British volume | December 2, 2005 | Volume: 87-B | Issue: 12 | Pages: 1702-1702

10.1302/0301-620x.87b12.16914 | PMID 15686232 Get It

Hürthle cell (oxyphilic) papillary thyroid carcinoma: A variant with more aggressive biologic behavior
Wu, Patricia S.-C., Goellner, John R., Ryan, John J., Ebersold, Jan R., Bergstralh, Erik J., Grant, Clive S., Herrera, Miguel F. , Hay, Ian , Ebersold, J R

World Journal of Surgery | August 13, 2005 | Volume: 16 | Issue: 4 | Pages: 669-674

10.1007/bf02067351 | PMID 1413835 Get It

AbstractThe latest World Health Organization International Classification defines papillary thyroid carcinoma by its “follicular cell differentiation. .. as well as characteristic nuclear changes”. However the oxyphilic (Hürthle cell) papillary carcinoma have nuclei which generally resemble the nuclei seen in oxyphilic follicular carcinomas, and such oxyphilic papillary tumors may behave more aggressively than typical papillary cancers. To further characterize these rare tumors, we identified during a 32‐year period 22 patients with oxyphilic papillary cancer and compared them with 1,084 patients with typical papillary cancers and 57 patients with oxyphilic follicular cancers treated by the Mayo surgical group during the same time period. Although typical papillary and oxyphilic papillary cancers were comparable with regards to patient age, tumor size and extent, TNM stage, and prognostic score (AGES), there were significant differences. Compared to typical papillary tumors, oxyphilic papillary cancers had fewer neck nodal metastases at primary diagnosis (5% vs 40%,p<0.0001), were more often DNA non‐diploid (71% vs 21%,p<0.001), and after 10 postoperative years had higher rates of both tumor recurrence (28% vs 11%,p<0.0001) and cause‐specific mortality (1.7% vs 4%,p<0.0005). In these four important respects the oxyphilic papillary cancers more resembled the oxyphilic follicular cancers. For oxyphilic follicular cancers, the frequency of initial neck nodal metastases was 7% (cf 5%); 83% of the oxyphilic follicular tumors were non‐diploid (cf 71%), and at 10 years postoperatively the tumor recurrence and cause‐specific mortality rates were 28% and 18%, insignificantly different from 28% and 17% seen with the oxyphilic papillary cancers. These results demonstrate that oxyphilic papillary tumors are more similar to oxyphilic follicular than typical papillary cancers, and suggest that in a differentiated follicular cell‐derived carcinoma a predominance of oxyphilic cells may be a prognostically more relevant feature than the individual tumor's predominant papillary or follicular morphologic pattern. Perhaps in future Histologic Classifications the World Health Organization should group the oxyphilic papillary cancers with the oxyphilic follicular rather than the typical papillary carcinomas.
International Staging System for Multiple Myeloma
Greipp, Philip R., Miguel, Jesús F. San , Durie, Brian G.M. , Crowley, John J., Barlogie, Bart , Bladé, Joan , Boccadoro, Mario , Child, J. A., Avet‐Loiseau, Hervé , Kyle, Robert A. , Morgan, Gareth J. , Powles, Raymond, Shimizu, Kazuyuki , Shustik, Chaim, Sonneveld, Pieter , Tosi, Patrizia , Turesson, Ingemar , Westin, Jan, Lahuerta, Juan José , Ludwig, Heinz , San-Miguel, Jesus , Morgan, Gareth J

Journal of Clinical Oncology | April 4, 2005 | Volume: 23 | Issue: 15 | Pages: 3412-3420

10.1200/jco.2005.04.242 | PMID 15809451 Get It

Purpose There is a need for a simple, reliable staging system for multiple myeloma that can be applied internationally for patient classification and stratification. Patients and Methods Clinical and laboratory data were gathered on 10,750 previously untreated symptomatic myeloma patients from 17 institutions, including sites in North America, Europe, and Asia. Potential prognostic factors were evaluated by univariate and multivariate techniques. Three modeling approaches were then explored to develop a staging system including two nontree and one tree survival assessment methodologies. Results Serum beta 2 -microglobulin (Sβ 2 M), serum albumin, platelet count, serum creatinine, and age emerged as powerful predictors of survival and were then used in the tree analysis approach. A combination of Sβ 2 M and serum albumin provided the simplest, most powerful and reproducible three-stage classification. This new International Staging System (ISS) was validated in the remaining patients and consists of the following stages: stage I, Sβ 2 M less than 3.5 mg/L plus serum albumin ≥ 3.5 g/dL (median survival, 62 months); stage II, neither stage I nor III (median survival, 44 months); and stage III, Sβ 2 M ≥ 5.5 mg/L (median survival, 29 months). The ISS system was further validated by demonstrating effectiveness in patients in North America, Europe, and Asia; in patients less than and ≥ 65 years of age; in patients with standard therapy or autotransplantation; and in comparison with the Durie/Salmon staging system. Conclusion The new ISS is simple, based on easy to use variables (Sβ 2 M and serum albumin), and recommended for early adoption and widespread use.
Transcutaneous partial pressure of oxygen after surgical wounds
McPhail, Ian R., Cooper, Leslie T. , Hodge, David O. , Cabanela, Miguel E., Rooke, Thom W. , Cooper, Leslie T

Vascular Medicine | September 25, 2004 | Volume: 9 | Issue: 2 | Pages: 125-127

10.1191/1358863x04vm539oa | PMID 15521702 Get It

Transcutaneous partial pressure of oxygen (TcPO2) predicts wound healing in critical ischemia. However, no studies have controlled for the effect of wounds on TcPO2. In this study, in 24 hip or knee arthroplasty cases without vascular disease, TcPO2 was measured preoperatively at the incision site, contralaterally, and at a reference site on the chest wall. The measurements were repeated at 2 days and 2 months postoperatively and compared. TcPO2, normal preoperatively, decreased at all sites on the second postoperative day (p < 0.001), with a trend toward a greater decrease at the wound (p 1/4 0.09). All wounds healed, and TcPO2 returned to baseline at all sites 2 months postoperatively. In conclusion, acute surgical wounds are associated with a significant and widespread decrease in cutaneous TcPO2 in the setting of normal arterial perfusion. This decrease is likely multifactorial and deserves further investigation.
Protective role of major histocompatibility complex class II Ebd transgene on collagen-induced arthritis.
Nabozny, Gerald , Bull, Marilyn J., Zanelli, Eric , Douhan, John, Glimcher, L H, Luthra, H. S., David, C S, González‐Gay, Miguel Á. , Griffiths, Marie

The Journal of experimental medicine | June 24, 2004 | Volume: 180 | Issue: 4 | Pages: 1559-1564

10.1084/jem.180.4.1559 | PMID 7931088 Get It

Collagen-induced arthritis (CIA) is an animal model of autoimmune inflammatory polyarthritis that has features similar to rheumatoid arthritis (RA). Much like RA, susceptibility to mouse CIA is influenced by the major histocompatibility complex (MHC), H-2, and restricted to the H-2q and H-2r haplotypes. Whereas the role of the H-2A molecule in susceptibility to CIA is well established, little is known about the role of H-2E molecule in the disease. In this study, we analyzed the effect of a transgenic E beta d molecule on CIA susceptibility in a recombinant mouse B10.RQB3, which expresses the CIA susceptible Aq genes and an Eak gene, but does not produce an E molecule since Ebq is nonfunctional. In the presence of an Ebd transgene, a viable E molecule is generated. Whereas B10.RQB3 were susceptible to CIA, B10.RQB3-E beta d+ showed a dramatic reduction in the incidence of arthritis as well as a decrease in the level of anti-mouse and anti-bovine CII antibodies in their serum. No clear cut differences in the expression of T cell receptor (TCR) V beta was observed between E beta d+ and E beta d- transgenic mice. Mechanisms underlying the protective effect of E beta d transgenic molecule on CIA may shed light on how HLA-DR molecules influence human RA.